Price as of · delayed, not real-time
Previously focused on developing and commercializing pharmaceutical therapies, this biopharmaceutical company was known for its work on treatments for renal disease. Investors followed it due to its specialized pipeline and potential in niche therapeutic areas before its market cap dwindled to zero.
3 members of Congress have disclosed 6 trades in Keryx Biopharmaceuticals, Inc. (KERX), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-02-10 | DEBBIE WASSERMAN SCHULTZ | buy | $1K – $15K |
| 2016-12-12 | DEBBIE WASSERMAN SCHULTZ | buy | $1K – $15K |
| 2016-12-12 | DEBBIE WASSERMAN SCHULTZ | buy | $1K – $15K |
| 2016-06-15 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2016-04-27 | DEBBIE WASSERMAN SCHULTZ | buy | $1K – $15K |
| 2015-05-27 | Thomas MacArthur | sell | $1K – $15K |